KR102201086B1 - Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 - Google Patents

Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 Download PDF

Info

Publication number
KR102201086B1
KR102201086B1 KR1020190113659A KR20190113659A KR102201086B1 KR 102201086 B1 KR102201086 B1 KR 102201086B1 KR 1020190113659 A KR1020190113659 A KR 1020190113659A KR 20190113659 A KR20190113659 A KR 20190113659A KR 102201086 B1 KR102201086 B1 KR 102201086B1
Authority
KR
South Korea
Prior art keywords
leu
ser
glu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020190113659A
Other languages
English (en)
Korean (ko)
Other versions
KR102201086B9 (ko
KR20200032009A (ko
Inventor
장명호
Original Assignee
(주)지아이이노베이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)지아이이노베이션 filed Critical (주)지아이이노베이션
Publication of KR20200032009A publication Critical patent/KR20200032009A/ko
Priority to KR1020210000775A priority Critical patent/KR102558191B1/ko
Application granted granted Critical
Publication of KR102201086B1 publication Critical patent/KR102201086B1/ko
Publication of KR102201086B9 publication Critical patent/KR102201086B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020190113659A 2018-09-17 2019-09-16 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 Active KR102201086B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210000775A KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20180110698 2018-09-17
KR1020180110698 2018-09-17
KR20190001867 2019-01-07
KR1020190001867 2019-01-07
US201962832013P 2019-04-10 2019-04-10
US62/832,013 2019-04-10
KR20190053436 2019-05-08
KR1020190053436 2019-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210000775A Division KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Publications (3)

Publication Number Publication Date
KR20200032009A KR20200032009A (ko) 2020-03-25
KR102201086B1 true KR102201086B1 (ko) 2021-01-11
KR102201086B9 KR102201086B9 (ko) 2022-10-21

Family

ID=69887592

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020190113659A Active KR102201086B1 (ko) 2018-09-17 2019-09-16 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
KR1020210000775A Active KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210000775A Active KR102558191B1 (ko) 2018-09-17 2021-01-05 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도

Country Status (22)

Country Link
US (4) US11492384B2 (https=)
EP (2) EP3715367B1 (https=)
JP (2) JP7085644B2 (https=)
KR (2) KR102201086B1 (https=)
CN (2) CN118725141A (https=)
AU (1) AU2019343850B2 (https=)
CA (1) CA3086486A1 (https=)
CL (1) CL2020001872A1 (https=)
DK (1) DK3715367T3 (https=)
ES (1) ES2985387T3 (https=)
FI (1) FI3715367T3 (https=)
HU (1) HUE068059T2 (https=)
IL (1) IL275592B (https=)
MX (1) MX2020007072A (https=)
PE (1) PE20201418A1 (https=)
PH (1) PH12020551026A1 (https=)
PL (1) PL3715367T3 (https=)
PT (1) PT3715367T (https=)
SG (1) SG11202005873QA (https=)
TW (2) TWI824258B (https=)
WO (1) WO2020060122A1 (https=)
ZA (1) ZA202003645B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021187904A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
WO2021187897A1 (ko) 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
WO2021187922A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
US12378526B2 (en) 2019-11-20 2025-08-05 Gi Cell, Inc. Composition for culturing natural killer cells and method for preparing natural killer cells by using same
US12516290B2 (en) 2019-11-20 2026-01-06 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
US20230014358A1 (en) * 2019-11-27 2023-01-19 Gi Cell, Inc. Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein
AU2020391280B2 (en) * 2019-11-27 2024-06-06 Gi Cell, Inc. Composition for anticancer treatment, comprising NK cells and fusion protein which comprises IL-2 protein and CD80 protein
WO2021201615A1 (ko) * 2020-03-31 2021-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
WO2021238904A1 (zh) * 2020-05-25 2021-12-02 北京比洋生物技术有限公司 Fc-CD80融合蛋白和其缀合物以及它们的用途
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
KR102313505B1 (ko) * 2020-06-30 2021-10-18 (주)지아이이노베이션 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
TW202216745A (zh) * 2020-07-02 2022-05-01 美商英伊布里克斯公司 包含經修飾ｉｌ－２多肽之多肽及其用途
WO2022045849A1 (ko) * 2020-08-31 2022-03-03 주식회사 지아이셀 Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
WO2022057696A2 (zh) * 2021-09-08 2022-03-24 中南大学湘雅医院 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法
WO2023234743A1 (ko) * 2022-06-03 2023-12-07 (주)지아이이노베이션 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도
WO2023249425A1 (ko) * 2022-06-22 2023-12-28 ㈜지아이이노베이션 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
EP4591873A4 (en) * 2022-09-20 2026-02-25 Gi Biome Inc Polytherapy including a strain of Lactobacillus plantarum and a cancer treatment method using it
WO2024063546A1 (ko) 2022-09-20 2024-03-28 주식회사 지아이바이옴 락토바실러스 플란타룸 균주의 병용 요법 및 이를 이용한 암 치료 방법
CN115850436B (zh) * 2022-10-14 2026-02-03 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2025063755A1 (ko) * 2023-09-20 2025-03-27 주식회사 에스엘바이젠 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160175397A1 (en) 2014-08-29 2016-06-23 Hoffmann-La Roche Inc. Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018184964A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71275A0 (en) * 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
CN86104525A (zh) * 1985-07-31 1987-02-25 武田药品工业株式会社 人类白细胞介素-2的分析方法和试剂
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
GB9810999D0 (en) 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7371371B2 (en) * 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CU23229A1 (es) 2002-05-10 2007-09-26 Ct Ingenieria Genetica Biotech ANTAGONISTA QUIMéRICO ANTH1
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
EP2402754B2 (en) * 2006-03-06 2023-07-26 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
ES2699599T3 (es) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
AU2016350701B2 (en) * 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR102687530B1 (ko) * 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11492384B2 (en) 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160175397A1 (en) 2014-08-29 2016-06-23 Hoffmann-La Roche Inc. Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018184964A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY Vol. 11, No. 1, pp 120-131 (2005.1.)*

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378526B2 (en) 2019-11-20 2025-08-05 Gi Cell, Inc. Composition for culturing natural killer cells and method for preparing natural killer cells by using same
US12516290B2 (en) 2019-11-20 2026-01-06 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
WO2021187904A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
WO2021187897A1 (ko) 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
WO2021187922A1 (ko) * 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
KR20210117200A (ko) 2020-03-18 2021-09-28 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
KR20230160763A (ko) 2020-03-18 2023-11-24 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
US11857601B2 (en) 2020-03-18 2024-01-02 Gi Innovation, Inc. Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug

Also Published As

Publication number Publication date
CA3086486A1 (en) 2020-03-26
TWI755630B (zh) 2022-02-21
KR20210008110A (ko) 2021-01-20
ES2985387T3 (es) 2024-11-05
EP4403635A3 (en) 2024-09-18
US20220380781A1 (en) 2022-12-01
BR112020015030A2 (pt) 2021-03-16
SG11202005873QA (en) 2020-07-29
CN111971295B (zh) 2024-08-02
US20250230212A1 (en) 2025-07-17
WO2020060122A1 (ko) 2020-03-26
IL275592A (en) 2020-08-31
EP3715367A1 (en) 2020-09-30
FI3715367T3 (fi) 2024-07-23
EP4403635A2 (en) 2024-07-24
JP2022115876A (ja) 2022-08-09
PE20201418A1 (es) 2020-12-09
TW202136288A (zh) 2021-10-01
CN118725141A (zh) 2024-10-01
TW202028227A (zh) 2020-08-01
KR102558191B1 (ko) 2023-07-24
DK3715367T3 (da) 2024-07-29
HUE068059T2 (hu) 2024-12-28
TWI824258B (zh) 2023-12-01
IL275592B (en) 2022-02-01
JP7085644B2 (ja) 2022-06-16
EP3715367B1 (en) 2024-06-12
ZA202003645B (en) 2022-09-28
AU2019343850A1 (en) 2020-06-25
MX2020007072A (es) 2020-11-11
AU2019343850B2 (en) 2024-06-06
JP2021511081A (ja) 2021-05-06
US12286464B2 (en) 2025-04-29
CN111971295A (zh) 2020-11-20
EP3715367A4 (en) 2021-05-05
PL3715367T3 (pl) 2024-09-02
JP7569820B2 (ja) 2024-10-18
US11492384B2 (en) 2022-11-08
KR102201086B9 (ko) 2022-10-21
US12291555B2 (en) 2025-05-06
KR20200032009A (ko) 2020-03-25
PT3715367T (pt) 2024-07-25
PH12020551026A1 (en) 2021-09-06
US20200369740A1 (en) 2020-11-26
CL2020001872A1 (es) 2020-12-18
US20220389070A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
KR102201086B1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
KR102940517B1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
KR102440962B1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
US20230104217A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
KR20210117208A (ko) Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
KR20210065874A (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물
RU2811541C2 (ru) Слитый белок, включающий белок il-2 и белок cd80, и его применение
RU2828377C1 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая слитый белок, содержащий белок il-2 и белок cd80, и ингибитор иммунной точки контроля
HK40032574A (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
HK40032574B (zh) 包含il-2蛋白和cd80蛋白的融合蛋白及其用途
BR112020015030B1 (pt) Proteína de fusão compreendendo il-2 e cd80, dímero da dita proteína, usos dos mesmos para tratar câncer, bem como polinucleotídeo, vetor, microorganismo transformado e composição farmacêutica
BR122024021342A2 (pt) Proteína de fusão compreendendo il-2 e cd80, dímero da dita proteína, usos dos mesmos para tratar câncer ou uma doença infecciosa, bem como polinucleotídeo, vetor, célula transformada e composição farmacêutica

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

S15-X000 Recordation of exclusive voluntary license amended

St.27 status event code: A-4-4-S10-S15-lic-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20221021

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1022010860000

Gazette reference publication date: 20210111

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000